Along with other molecular markers such as the internal tandem duplication mutations in the FLT3 (FLT3‐ITD), which is an actionable vulnerability bearing a negative prognostic significance [5], the MRD has transformed the management of the patients with APL [4]. Here, FLT3 is linked to acute promyelocytic leukemia.